ELI LILLY & CoLLYバランスシート

時価総額
$1.01兆
PER
医薬品の研究開発・製造・販売の米国最大手。GLP-1系抗肥満薬や糖尿病薬、バイオ医薬品を含む製品群を展開。2023年12月にPOINTを約10.4億ドルで買収、2024年5月にウィスコンシンの製造施設を約9.25億ドルで買収。米国・欧州・日本・中国を中心に世界展開。
2010/122011/122012/122013/122014/122015/122016/122017/122018/122019/122020/122021/122022/122023/122024/12
現金同等物5,9935,9234,0193,8303,8723,6664,5826,5367,9982,3383,6573,8192,0672,8193,268
有価証券7349751,6661,5679557851,4571,498881012490145109155
現金 + 有価証券6,7276,8975,6845,3974,8274,4526,0398,0348,0862,4393,6813,9092,2122,9283,423
売掛金3,4943,5983,3363,4343,2353,5134,0294,5465,2474,5475,8756,6736,8969,09111,006
商品及び製品2,5182,3002,6442,9292,7403,4463,5624,4584,1123,1913,9803,8864,3105,7737,589
流動資産合計14,84014,24813,03913,10512,18012,57415,10119,20220,55013,71017,46218,45218,03525,72732,740
有形固定資産7,9417,7607,7607,9767,9648,0548,2538,8278,9207,8738,6828,98510,14412,91417,102
投資有価証券1,7804,0306,3137,6254,5693,6475,2085,6792,0211,9622,9673,2132,9023,0523,216
固定資産合計8,22111,65113,60014,16917,03514,94215,45216,95214,43925,57729,17130,35431,45538,27945,975
総資産31,00133,66034,39935,24937,17835,56938,80644,98143,90839,28646,63348,80649,49064,00678,715
買掛金1,0721,1251,1881,1191,1281,3381,3491,4111,4121,4051,6071,6711,9312,5993,229
流動負債合計7,1018,9318,3908,91711,2088,23010,98714,53611,88811,77512,48215,05317,13827,29328,377
長期借入金6,7715,4655,5194,2005,3687,9728,3689,94111,64013,81816,58715,34614,73818,32128,527
固定負債合計11,48711,19311,2368,69110,58312,74913,73918,77721,11124,81228,32624,59921,57625,84936,067
資本金及び資本剰余金721724717699695691689688661599598596594594592
利益剰余金12,73314,89816,08816,99216,48316,01216,04613,89411,3964,9207,8308,95910,04310,31213,545
株主資本12,41313,53614,77417,64115,38814,59014,08111,66810,9092,6995,8259,15510,77510,86414,272
有利子負債合計6,7715,4655,5194,2005,3337,9728,3689,9419,19613,81816,58715,34614,73818,32128,527
純有利子負債44-1,432-165-1,1975063,5212,3291,9061,11011,37912,90511,43812,52615,39325,104
DEレシオ(%)54.540.437.423.834.754.659.485.284.3511.9284.7167.6136.8168.6199.9
運転資本